Response rate of anticancer drugs approved by the Food and Drug Administration based on a single-arm trial.

Published in: BMC cancer (2022)

The lower limit of a 95% CI of the ORR of a new drug in an SAT exceeding the point estimate of the BCT ORR could be an important factor in obtaining regulatory approval.

Keyphrases

drug administration
phase iii
study protocol
clinical trial
phase ii
transcription factor
drug induced
human health
adverse drug
randomized controlled trial
open label
risk assessment
climate change
electronic health record